LBSP Favicon

Leiden Researchers Make Breakthrough in Duchenne Muscular Dystrophy

Leiden, 24 October 2025 at 3:03 PMResearchers at LUMC, together with colleagues from the University of Florida, have identified hundreds of proteins in the blood that provide information about the […]

Leiden, 24 October 2025 at 3:03 PM
Researchers at LUMC, together with colleagues from the University of Florida, have identified hundreds of proteins in the blood that provide information about the progression of Duchenne muscular dystrophy. The study, published in Nature Communications, brings a simple blood test a significant step closer.

Duchenne muscular dystrophy is a rare, hereditary muscle disease that primarily affects young boys. Their muscles progressively weaken, often leading to the use of a wheelchair around the age of ten. Tracking the progression of the disease is currently challenging, as doctors mainly rely on physical tests that are strenuous and not always reliable.

Less Burdensome
Researchers at Leiden University discovered that certain blood proteins, known as biomarkers, indicate how quickly the disease progresses and how well a patient can still walk or use their arms. These proteins can also show whether medications are having an effect. This makes patient care more personalized and less burdensome.

The LUMC has played a central role for years in research on Duchenne and Becker muscular dystrophy. Becker muscular dystrophy is a similar condition, but it is often diagnosed later and tends to have a less severe course.

Related posts

Labs31 moved to Leiden Bio Science Park

Labs31 moved to Leiden Bio Science Park

From the Van Nelle Factory to BioPartner 5, from heritage to future, from start-up to innovative lab design agency.  After an inspiring and innovative seven-year start at the...

November 14, 2025 Changed traffic situation

November 14, 2025 Changed traffic situation

Starting Friday, November 14 at 4:00 p.m., two temporary closures (in place for the duration of the Plesmanlaan project, until approximately Q3 2027) will be implemented for...